April 21, 2012 -- Fidelity Investments announced a new $250 million China VC fund, half of which will be devoted to healthcare; Daiichi Sankyo gained control of Shanghai Xinshengyuan Pharma, a company that imports generics from Ranbaxy Labs into China; Luqa Pharma of Hong Kong out-licensed Middle East/North Africa rights for a topical antifungal to NewBridge Pharma; the Di'ao Group gained approval in the European Union for a TCM cardiovascular drug; and Fluidigm, a US supplier of research tools for biological research, opened its own sales office in Shanghai. More details....
Stock Symbols: (TO: 4658) (BSE: 500359) (NSDQ: FLDM)
